Rapid growth in private medical-cannabis care has created access that the NHS largely failed to provide. It has also made the quality of private oversight a public-interest issue. When regulation identifies inconsistent assessment, records or follow-up, patients should not be asked to choose between gratitude for access and scrutiny of care.
Both are necessary.
What good care should look like
A credible clinic should obtain relevant medical history, explain benefits and risks, document why treatment is appropriate and provide a clear plan for monitoring. Prescribing is not a one-off transaction. Follow-up should test whether the medicine is helping, whether side effects are manageable and whether the plan needs to change.
Variation between clinics is not automatically evidence of poor care; patients and conditions differ. But unexplained variation in basic safeguards should concern the sector.
Why patients carry too much of the burden
In a fragmented market, patients often have to judge quality from prices, reviews and marketing claims before they have met a clinician. Those signals can help, but none substitutes for transparent governance and effective inspection.
Patients should be able to ask who is responsible for their care, how concerns are escalated, how frequently treatment is reviewed and what happens if a clinician leaves. A provider that cannot answer clearly is revealing something important.
Regulation must keep pace
The CQC's role is not to decide whether cannabis-based medicine is good or bad. It is to ensure that registered services meet standards expected of healthcare. Clinics, in turn, should see robust regulation as protection for legitimate practice rather than hostility to the sector.
Private access solved one part of the post-2018 problem. It cannot be allowed to create another in which speed and customer acquisition outrun clinical responsibility. The sector's long-term credibility depends less on how quickly it grows than on whether patients can trust the care behind each prescription.
